© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Researchers compared outcomes among those with and without hep C before and after Sovaldi was approved in late 2013.
Selonsertib did not improve liver fibrosis more than a placebo.
Curing the virus was associated with a lower risk of liver cancer recurrence.
These drugs are approved to treat all six major genotypes of hepatitis C.
The HepConnect initiative aims to expand testing, harm reduction and health care infrastructure.
The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.
A look at the supply chain that results in very high costs for HIV and hepatitis C medications.
The subscription-based model is the first of its kind.
The placebo-controlled trial Phase III trial of selonsertib had sought to improve fibrosis while not worsening NASH.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
